CV: Curriculum Vitae
Thomas M. Banas, M.D., M.S.
Discerning M.D., Inc.
11230 Dell Loch Way
Fort Wayne, IN 46814
Cell phone: (260) 466-1752
July 1992-August 2020: Neurologist, Fort Wayne Neurological Center. Expertise in stroke, epilepsy, TBI, concussion, neurological rehabilitation, movement disorders, spasticity and general neurology.
May 2021-present: Tele-neurology
August 2020-present Locums Neurology
1997-present: Independent Medical Examiner.
1997-2020: Assistant Professor Clinical Medicine, Indiana Medical School, Fort Wayne, Indiana.
July 2017-August 2020: Research Director, Fort Wayne Neurology.
June 2015-2019: Board Member, Chair of Indiana Neurological Society (INS) Membership Committee.
2018-2021: Executive Committee of American Neurological Society Industrial Relations Committee.
2016-present: Board of Directors Committee, Turnstone Center, Fort Wayne, Indiana.
2017-present: Committee Member, Young Life, Southwest of Fort Wayne.
1992-2016: Parkview Regional Medical Center Research Center, Fort Wayne, Indiana.
2010-2013: Medical Director/Chairman Rehab Hospital of Fort Wayne, Indiana.
2008-2012: Director of Neuroscience, Department of Medical Education, IPFW School of Medicine, Fort Wayne, Indiana.
2005-present: Stroke Care Now Network/Acute Stroke, Network of 27 Hospitals. Physician/Neurologist.
2009-2012: Stroke Director, Stroke Care Now Network, Northern Indiana.
1992-2016: Neurologic Rehabilitation Patient Care.
University of Cincinnati Medical Center, Neurology Resident, 1989-1992.
University of Cincinnati Medical Center, Department of Internal Medicine, Internship, Cincinnati, Ohio, 1988-1989.
University of Cincinnati School of Medicine, Cincinnati, Ohio, 1984-1988.
Case Western Reserve University Biomedical Engineering, Master of Science, Cleveland, Ohio, 1982-1984.
Case Western Reserve University Biomedical Engineering, Bachelor of Science, Cleveland, Ohio, 1977-1982.
University of Sussex, Falmer-Brighton, England, Junior Year 1979-1980.
HONORS AND AWARDS
1977 Case Western Alumni Scholar
Michigan Regent Alumni Scholar
1982 B.S. Degree in Biomedical Engineering with Honors
1984 M.S. Degree in Biomedical Engineering with High Honors
CURRENT MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS
American Academy of Neurology
American Board of Psychiatry & Neurology, Inc.
Ohio State Medical Association
Indiana State Medical Association
Fort Wayne Medical Association
State of Ohio (Permanent), ID #35.059816
State of Indiana, ID #01040131
State of Michigan, ID #M521386
State of North Carolina ID #260585
State of Arkansas ID #T2021-2022
Completion of Master's thesis entitled "Internal Changes in Muscle Gain Induced by Submaximal Intermittent Exercises."
Parkview Hospital, Fort Wayne, Indiana
St. Joseph Medical Center, Fort Wayne, Indiana
Lutheran Hospital, Fort Wayne, Indiana
Dupont Hospital, Fort Wayne, Indiana
Rehabilitation Hospital of Fort Wayne, Indiana
Wabash Hospital, Wabash, Indiana
Baptist Hospital, little Rock, Arkansas
Novant, North carolina
EMPLOYMENT PRIOR TO RESIDENCY
6/85 - 9/85 Consultant Engineer, Department of Physiology, University of Cincinnati, Cincinnati, Ohio
4/84-9/94 Engineer, Gait Laboratory, Veterans Administration Center, Cleveland, Ohio
9/83-4/84 Engineer, Rehabilitation Engineering Center/CWRU, Department of Orthopedics, Highland View Metro General Hospital, Cleveland, Ohio
1/78-9/81 Research Assistant, Applied Neural Control Laboratory, Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio
Collaborative Institutional Training Initiative (CITI)
2019 UCB Biopharma SPRL - A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy, Sub-Investigator
2018 Acadia Pharmaceuticals ACP-NIS-001 - An Observational Study on the Management of Parkinson's Disease Psychosis in Actual Practice, Primary Investigator
2018 F. Hoffmann - LaRoche - A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease, Sub-Investigator
2018 Alexion EC-NMO-302 - A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO), Sub-Investigator
2015 Alexion EC-NMO-301 - A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center trial to evaluate the safety and efficacy of Eculizumab in patients with Neuromyelitis Optica (NMO), Sub-Investigator
2015 Biogen 101MS413 - A Phase IV Multicenter, Open-Label study to evaluate whether a Medication Event Monitoring System (MEMS®) can improve adherence to Tecfidera (delayed-release dimethyl fumarate) treatment in MS patients, Sub-Investigator
2014 Biogen 101MS409 - A Phase III Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis, Sub-Investigator
2013 Sanofi Aventis LPS13567 - A Prospective, Single-Arm, Clinical-Setting, Study to Describe Efficacy, Tolerability and Convenience of AUBAGIO Treatment Using Patient Reported Outcomes in Relapsing Multiple Sclerosis Patients
2013 Teva LAQ MS 305 - A multinational, multicenter, randomized, double blind, parallel Group placebo controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of Laquinimod in subjects with Relapsing Remitting Multiple Sclerosis
2011 Pfizer, Inc.: A0081242- A phase 3B multicenter, double-blind, randomized withdrawal efficacy and safety study of Pregabalin in the treatment of patients with inadequately treated painful diabetic peripheral neuropathy, Principal Investigator
2010 Biogen Idec: 101MS325 - A multicenter, randomized, rater-blind, parallel-group, active controlled study to evaluate the benefits of switching therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in subjects with relapsing remitting multiple sclerosis, Sub-Investigator
2010 Sanofi-Aventis: EFC6058 - A multicenter, double-blind, parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta, Sub-Investigator
2010 Sanofi-Aventis: LTS6050 - A long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses, Sub-Investigator
2010 Biogen Idec: 205MS301 - A multicenter, double-blind randomized, parallel-group monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in patients with relapsing-remitting multiple sclerosis, Sub-Investigator
2010 Biogen Idec: 101JC402 - A JCV antibody program in patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri®, STRATIFY-2, Sub-Investigator
2009 Cephalon: C10953/3067 - An open-label study to evaluate the safety, tolerability, and efficacy of armodafinil (150 and 250) mg/day) as treatment for patients with
excessive sleepiness associated with mild or moderate closed traumatic brain injury, Sub-Investigator
2009 Octapharma: GAM-10-04, double-blind, randomized, multicenter, placebo-controlled dose-finding study evaluating the amyloid beta reduction in the cerebrospinal fluid and increase in the blood plasma after treatment with intravenous immunoglobulin in mild to moderate Alzheimer's disease, Sub-Investigator
2008 Sanofi-Aventis: EFC10531 - A multi-center, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis using Interferon-Beta 1a (Rebif®) as an open-label rater-blind calibrator, Sub-Investigator
2008 UCB: RPCE07F1214-historical-control conversion to monotherapy to evaluate the efficacy and safety of brivaracetam, with partial onset seizures with or without secondary generalization, Principal Investigator.
2008 UCB: RPCE08C0502-follow-up study to evaluate the long-term safety and efficacy of brivaracetam used at flexible dose up to a max of 150 mg/day, Principal Investigator
2008 Sanofi-Aventis: EFC6260 - An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis, plus a long-term extension period, Sub-Investigator
2007 Sanofi-Aventis: EFC6049, a randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of a teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses, Sub-Investigator
2007 Alza: C2006-028-03 - A single dose JNJ-17216498 for narcolepsy patients, Sub-Investigator
2007 Eisai, Inc.: E2020-G300-328 - Double-blind, parallel group comparison of 23 mg Donepezil sustained release to 10 mg Donepezil immediate release in patients with moderate to severe Alzheimer's Disease, Sub-Investigator
2007 Eisai, Inc.: E2020-G300-326 - A comparison of 23 mg Aricept SR with 10 mg Aricept IR in patients with moderate to severe Alzheimer's disease, Sub-Investigator
2007 Sanofi-Aventis: Teriflunomide in patients with relapsing MS, Sub-Investigator
2007 Sanofi-Aventis: Teriflunomide in patients with a first clinical episode suggestive of multiple sclerosis, Sub-Investigator
2007 Teva: PM028 - Evaluate the effect of regularly scheduling neutralizing antibody testing on treatment patterns versus usual care in IFN treated patients, Principal Investigator
2007 SAPPHIRE: Registry for carotid stenting with the PRECISE stent system and angioplasty with protection in patients at high risk for endarterectomy, Sub-Investigator
2007 SONOMA: Registry for carotid stenting with the NexStent system in conjunction with the FilterWire EZ embolic protection system, Sub-Investigator
2006 NTI: NTI-ASP-0502- A Viprinex (Ancrod) for acute ischemic stroke patients administered within 6 hours of onset, Sub-Investigator
2006 Biogen Idec: Serologic study to correlate B-IFN NAb titers to B-IFN induced biomarker response in MS patients, Sub-Investigator
2006 Depomed: 81-0045: Gabapentin Extended Release in treatment of patients with post-therapeutic neuralgia, Principal Investigator
2005 Abbott: ABT-874 M03-654 - A compound ABT874 for patients with Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis, Sub-Investigator
2005 Biogen Idec: C-870: Avonex for patients with CIDP, Sub-Investigator
2005 Chant: 72-hour infusion for Intracranial Hemorrhage, Sub-Investigator
2005 NMT Medical: Closure I: Starflex Closure system in patients with Patent Foramen Ovale, Principal Investigator
2005 Forest: Bolus of thrombolytic in Acute Ischemic Stroke, Sub-Investigator
2005 ONO: Neuroprotective infusion for Acute Ischemic Stroke, Sub-Investigator
2005 Pfizer: Neuroprotective infusion for Acute Ischemic Stroke, Sub-Investigator
2005 Saint II: Neuroprotective infusion for Acute Ischemic Stroke, Sub-Investigator
2004 Sceptre: NS2330 in early Parkinson's patient, Sub-Investigator
2004 Biogen Idec: C865-Avonex, Methotrexate or IV Methylprednisolone in Relapsing-Remitting Multiple Sclerosis, Sub-Investigator
2003 ACT: Avonex, Methotrexate or IV Methylprednisolone in Relapsing-Remitting Multiple Sclerosis, Sub-Investigator
2003 Bayer: Above: Betaseron vs. Avonex Relapsing-Remitting Multiple Sclerosis, Sub-Investigator
2003 CREST: Carotid Revascularization Endarterectomy vs. Stenting, Sub-Investigator
2003 Orphan: Treatment of narcolepsy patients with Xyrem, Sub-Investigator
2002 Schwarz: SP512 - Rotigotine in early stage Parkinson's disease, Principal Investigator
2002 Schwarz: SP650 - Rotigotine in advance stage Parkinson's disease, Sub-Investigator
2001 Bayer: Beyond: Betaseron vs. double dose Betaseron vs. Copaxone in relapsing-remitting multiple sclerosis, Sub-Investigator
2002 Evaluate Patients with Acute Stroke given Tissue Plasminogen Activator + YM872
2002 ARTIST MRI Acute Stroke-Evaluate Effects of YM872 Infusions on lesion volume
2002 Elan Epilepsy Study, Principal Investigator
2002 Deep Brain Stimulator for Parkinson's Disease Indiana University Purdue University Fort Wayne
2002 Pfizer Alzheimer's Disease Study, Sub-Investigator
2002 Security Carotid Stent Study, Sub-Investigator
2001 Tolerability of Rebif injections with use of Rebiject device in relapsing-remitting multiple sclerosis patients
2001 Mitoxantrone: Study of Side Effects in Multiple Sclerosis
2001 Zonegran as Monotherapy in patients with newly diagnosed Epilepsy: Principal Investigator
2001 Oral CP-457, 920 and Donepezil in Outpatients with Alzheimer's disease.
2000 ASTA-MEDICA Chronic Pain, Sub-Investigator
2001 Pfizer-Stroke Treatment Study 0-6 hour window, Sub-Investigator
2001 ARTIST MRI Acute Ischemic Stroke Study. Sub-Investigator
2001 ARTIST + Acute Ischemic Stroke Study, Sub-Investigator
2001 Immunex Multiple Sclerosis Study, Sub-Investigator
2001 IDE Carotid Stent Study, Sub-Investigator
1998 Stroke Treatment with Ancrod Trial, 0-3 hour window, Sub-Investigator
1998 Thrombolytic Therapy in Acute Ischemic Stroke (rt-PA) 0-3 hour window, Sub-Investigator
1998 Gabitril Monotherapy Seizure Study
1998 GAIN III Stroke Treatment Study, 0-6 hour window, Principal Investigator
1997 COP-1 Treatment study 3-5 hour window, Sub-Investigator
1997 Atlantis Stroke Treatment Study, 3-5 hour window, Sub-Investigator
1997 Topiramate Epilepsy Trial, Sub-Investigator, Study closed by sponsor
1997 Gain II Stroke Treatment Study, 0-12 hour window, Sub-Investigator
1997 Fiblast Stroke Treatment Study, 0-6 hour window, Sub-Investigator
1997 M.I.N.T. Alzheimer Study, Principal Investigator